Preclinical Research
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development
LAVAL, Québec, and RADNOR, PA. — May 7, 2026 — Altasciences, a fully integrated drug development solution company, and Certara, a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs.
Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach.
Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies are refined, and programs are more seamlessly integrated across nonclinical, clinical, bioanalytical, and manufacturing services.
“At Altasciences, we already help sponsors move from first safety assessment to proof of concept with speed and precision,” said Marie-Hélène Raigneau, CEO of Altasciences. “By embedding Certara’s modeling capabilities into our platform, we can further inform critical decisions earlier and with greater confidence. This collaboration is about reducing uncertainty at the moments that matter most.”
The partnership comes at an opportune time as the FDA continues to advance new guidance supporting more adaptive, data-driven, and real-time drug development approaches, capabilities that integrated MIDD execution models are well positioned to deliver.
“This partnership unlocks new opportunities to improve early development decisions for biotech sponsors and their investors,” said Jon Resnick, CEO of Certara. “By embedding modeling and simulation directly into execution, we enable faster, more informed decision-making that ultimately benefits patients.”
Together, Altasciences and Certara are advancing a model-first, fully integrated, and resource-efficient approach to early drug development that accelerates the path to proof of concept for biotech innovators, investors, and pharmaceutical companies across the globe.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, research support, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
Julie-Ann Cabana
Altasciences
media@altasciences.com
JAK1-siRNA Treatment for Inflammatory Skin Diseases: Real-World Nonclinical Insights
Findings shared here were originally presented in a poster session at ACT 2025
Navigating to the Clinic: Key Aspects of Translational Pharmacology, By Bruce Morimoto
Drug development is not for the faint of heart; a twist on the Hunger Games saying, “May the odds be (n)ever in your favor,” might adequately characterizes the challenge. As scientists, however, we manage these inherent risks by establishing best practices and learning from our collective successes and failures, as well as. In this field, experience truly matters.
First-in-Human-Enabling Toxicology Programs: Common Misconceptions by Grace M. Furman
Nomination of a clinical candidate and subsequent conduct of toxicology studies to support a first-in-human (FIH) clinical trial is an exciting milestone for sponsors! While many are highly experienced drug discovery professionals, some may have limited, or even no experience, in early clinical development, including the critical toxicology studies required to successfully support a FIH trial.